17-alpha-estradiol
17-alpha-estradiol, non-feminising estradiol stereoisomer
Written by Aaron CuhaReviewed Sep 2026
Also known as: 17a-estradiol, Alfatradiol
One of the most reliably replicated lifespan extenders in mice, robust at higher doses and even when started late in life. It does not work in females, and nobody knows why.
Overview
This is among the strongest pharmacological lifespan results in existence, and it comes with a caveat so large that most coverage simply omits it.
17-alpha-estradiol is the mirror-image stereoisomer of the main human estrogen. The alpha configuration means it binds classical estrogen receptors weakly, so it does not produce the feminising effects the beta form does, which is why it can be given to male animals at all.
In the Interventions Testing Program it extended lifespan robustly. At a threefold higher dose it extended both median and maximal lifespan, and a separate cohort found benefit even when treatment began late in life, which is the property almost no lifespan intervention has.
In every one of those experiments the effect was confined to males. Not reduced in females. Absent.
Mechanism of action
The stereoisomer of 17-beta-estradiol at carbon 17, which drops its affinity for classical estrogen receptors by orders of magnitude and removes the feminising activity. Because it is not acting as a conventional estrogen, the mechanism behind its lifespan effect is genuinely unresolved. Reported effects include reduced hypothalamic inflammation, improved hepatic insulin sensitivity, reduced mTOR signalling in liver, and changes in markers of metabolic health. The sex specificity is central to the puzzle: if the compound worked through a non-hormonal metabolic route, there is no obvious reason it should not work in females, and it does not.
Human evidence
None for ageing. No human trial has examined lifespan, healthspan or any geroscience endpoint with this compound.
- No human study of 17-alpha-estradiol for ageing, healthspan or metabolic health was located.
- Topical preparations are marketed in some European countries for androgenetic alopecia, which is a different route, dose and purpose.
- All lifespan evidence is in mice, fed continuously in the diet.
What this does not tell you: The entire case is a mouse result, and a sex-restricted one. Translating a compound whose benefit appears only in males and whose mechanism is unresolved would require knowing what that mechanism is, and nobody does. The topical hair loss use tells you nothing about systemic exposure at lifespan-relevant doses.
Reading the research record
The male-specific pattern is the most under-discussed finding in this whole field. Several of the programme's most reliable positives extend lifespan in male mice and not in female mice, and the effect is not a matter of statistical power: the female curves simply do not move. Nobody has established why. Proposed explanations include differences in drug metabolism, in baseline mortality causes between the sexes in this strain, and in hormonal context. What it means practically is that a headline reading a compound extends lifespan in mice is frequently describing an effect in half the animals, and that half is usually not stated.
The Interventions Testing Program is run by the National Institute on Aging at three independent sites, using UM-HET3 mice, a genetically heterogeneous four-way cross, so a result cannot be an artefact of one inbred strain. Both sexes are tested, cohorts are large enough to detect roughly a 10 percent change in lifespan, and nulls are published alongside positives. Nothing else in ageing research has that combination, which is why its results carry more weight than a single-laboratory finding and why its failures to replicate are worth as much attention as its successes.
The evidence, charted
Fig. 1 · evidence composition
0of 4 citations (0%) are in people
Every citation cited here is Animal work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2014 to 2021, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, prescription route in 0, not approved in 3. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2016
Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an alpha-glucosidase inhibitor or a Nrf2-inducer
Interventions Testing Program. 17-alpha-estradiol at a threefold higher dose than previously tested robustly extended both median and maximal lifespan, still only in males. The same paper reports nordihydroguaiaretic acid replicated in males at the original dose and at threefold lower and higher doses, dose-dependently and without an effect on maximal lifespan, and that Protandim extended median lifespan in males only. It also reports that neither fish oil nor ursodeoxycholic acid extended lifespan, and that metformin alone at 0.1 percent of diet did not significantly extend lifespan while metformin combined with rapamycin robustly did.
Aging Cell - Animal2014
Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males
The original report establishing the male-preferential pattern for all three compounds. This is the paper that made sex specificity a central question in the field rather than a footnote.
Aging Cell - Animal2021
17-alpha-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex
The late-start result, which is the property that makes this compound unusual: benefit when treatment began late in life, in males. The same cohort reports that nicotinamide riboside and three other compounds did not affect lifespan in either sex, which is the relevant null for anyone taking an NAD precursor.
Aging Cell - Animal2017
Anti-aging drugs reduce hypothalamic inflammation in a sex-specific manner
A mechanistic follow-up asking why these effects are sex-specific, reporting that the reduction in hypothalamic inflammation itself differs by sex. A partial answer rather than a resolution.
Aging Cell
Frequently asked questions
Does 17-alpha-estradiol extend lifespan?
In male mice, robustly and repeatedly, including at higher doses where it extended maximal as well as median lifespan and when started late in life. In female mice, not at all. There is no human data of any kind.
Will it feminise a man?
That is the point of the alpha stereoisomer: it binds classical estrogen receptors far more weakly than the beta form, so it lacks the feminising activity. That is also why the mechanism is unresolved, because it is not acting as a conventional estrogen.
Why does it only work in males?
Nobody has established this, and it is the most interesting open question in the field. Candidate explanations include sex differences in drug metabolism, in what actually kills these mice, and in hormonal context. A mechanistic follow-up found that even the reduction in hypothalamic inflammation differs by sex.
Should I take it?
There is nothing to take. It is not approved anywhere for a systemic indication, there is no human ageing data, and the evidence is a mouse result in one sex with an unknown mechanism.